Seaport Therapeutics(NASDAQ) SPTX

Seaport Therapeutics, Inc. makes medicines for depression and anxiety. It helps drugs reach the brain more effectively. These treatments aim to reduce dangerous side effects.

New Ways to Deliver Medicine

• GlyphAllo: Oral drug for major depressive disorder; currently undergoing a Phase 2b clinical trial to test its effectiveness.
• GlyphAgo: Medicine for generalized anxiety disorder; designed to bypass the liver to reduce the risk of organ damage.
• Glyph2BLSD: Experimental treatment for brain and headache disorders; uses a nonhallucinogenic version of LSD that does not cause hallucinations.
• Glyph Platform: Delivery technology that uses natural lipid pathways to help medicine enter the body without being broken down by the liver.

Growing the Clinical Pipeline

• Acquired the proprietary Glyph technology assets from PureTech Health in April 2024.
• Raised $100.1 million in gross proceeds through a Series A-2 financing round in April 2024.
• Secured $226.0 million in gross proceeds from a Series B financing round in October 2024.
• Completed an initial public offering on May 1, 2026, which raised $238.4 million in net proceeds.

Solving the Liver Safety Problem

Seaport uses its Glyph technology to change how the body processes medicine by bypassing the liver. This method allows the company to develop oral versions of drugs that previously caused safety concerns or had poor absorption.

A Look at the Numbers

• Net loss was $88.0 million for the six months ended June 30, 2026, compared to $28.2 million for the same period in 2025.
• Research and development expenses increased to $46.0 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026.
• The company reported an accumulated deficit of $202.1 million as of June 30, 2026.
• Market capitalization was $1.1 billion during the first quarter of 2026.

Company Evolution

Seaport has transitioned from a private technology developer into a public clinical-stage biotechnology firm. It focuses on using proprietary delivery systems to improve treatments for complex brain conditions.